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Abstract
The fate of breast cancer patients is dependent upon elimination or control of metastases. We studied the effect of
antibody-targeted liposomes containing entrapped doxorubicin (DXR) on development of tumours in two models of breast
cancer, pseudometastatic and metastatic, in mice. The former used the mouse mammary carcinoma cell line GZHI, which
expresses the human MUC-1 gene (L. Ding, E.N. Lalani, M. Reddish, R. Koganty, T. Wong, J. Samuel, M.B. Yacyshyn, A.
Meikle, P.Y.S. Fung, J. Taylor-Papadimitriou, B.M. Longenecker, Cancer Immunol. Immunother. 36 (1993) 9^17). GZHI
cells seed into the lungs of Balb/c mice following intravenous injection. The latter used the 4T1-MUC1 cell line, a MUC-1
transfectant of the mouse mammary carcinoma cell line 4T1, which metastasizes from a primary mammary fatpad (mfp)
implant to the lungs (C.J. Aslakson, F.R. Miller, Cancer Res. 52 (1992) 1399-1405). B27.29, a monoclonal antibody against
the MUC-1 antigen, was used to target sterically stabilized immunoliposomes (SIL[B27.29]) to tumour cells. In vitro,
SIL[B27.29] showed high specific binding to both GZHI and 4T1-MUC1 cells. The IC50 of DXR-loaded SIL[B27.29] was
similar to that of free drug for GZHI cells. In the pseudometastatic model, mice treated with a single injection of 6 mg DXR/
kg in DXR-SIL[B27.29] at 24 h after cell implantation had longer survival times than those injected with non-targeted
liposomal drug. In the metastatic model, severe combined immune deficiency mice given weekly injectionsU3 of 2.5 mg
DXR/kg encapsulated in either targeted or non-targeted liposomes were almost equally effective in slowing growth of the
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Abbreviations: MPS, mononuclear phagocyte system; DXR, doxorubicin; HSPC, hydrogenated soy phosphatidylcholine; PEG-DSPE,
polyethylene glycol (Mr 2000) covalently coupled to distearoylphosphatidylethanolamine; CHOL, cholesterol ; PL, phospholipid; PDP-
PEG-DSPE, pyridyldithiopropionamide-polyethylene glycol (Mr 2000)-distearoylphosphatidylethanolamine; MCS, O-maleimidocaproic
acid N-hydroxysuccinimide ester; PBS, phosphate-bu¡ered saline; DTT, dithiothreitol ; HEPES, 4-(2-hydroxyethyl)piperazine-1-ethane-
sulphonic acid; MES, 2-(4-morpholino)ethanesulphonic acid; SL, sterically stabilized (Stealth) liposomes; SIL, sterically stabilized
(Stealth) immunoliposomes; mAb, monoclonal antibody; NSAb, non-speci¢c antibody (mAb HMSA-5); MST, mean survival time;
IC50, 50% inhibitory concentration; mfp, No. 4 mouse mammary fatpad; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide; SCID, severe combined immune de¢ciency; 125I-dUrd, 5-[125I]iododeoxyuridine; FITC, £uorescein isothiocyanate; HER2, a
member of the erbB family of growth factor receptors
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primary tumour and reducing development of lung tumours. Surgical removal of the primary tumour from mfp, followed by
various chemotherapy regimens, was attempted, but removal of the primary tumour was generally incomplete ; tumour
regrowth occurred and metastases developed in the lungs in all treatment groups. DXR-SL reduced the occurrence of
regrowth of the primary tumour, whereas neither targeted liposomal drug or free drug prevented regrowth. We conclude that
monoclonal antibody-targeted liposomal DXR is effective in treating early lesions in both the pseudometastatic and
metastatic models, but limitations to the access of the targeted liposomes to tumour cells in the primary tumour compromised
their therapeutic efficacy in treating the more advanced lesions. ß 2001 Elsevier Science B.V. All rights reserved.
Keywords: Liposome; Breast cancer; Drug targeting; Metastasis ; MUC-1; Stealth liposome; Doxorubicin
1. Introduction
One of the major problems for patients who su¡er
from breast cancer is the metastatic spread of cells
from the primary tumour [3]. Preventing the meta-
static spread of cancer cells through the circulation in
an adjuvant setting may be a practical way to man-
age this disease. The anticancer drug doxorubicin
(DXR), which is widely used in the treatment of
breast cancer (either alone or in combination with
other chemotherapeutics), may reduce the occurrence
of micrometastasis, but bone marrow and cardiac
toxicity limit its clinical value [4]. Drug carriers like
liposomes can enhance the localization of chemo-
therapeutic drugs in solid tumours and decrease
drug uptake by sensitive organs, resulting in reduced
toxicity. A long-circulating (Stealth) liposomal for-
mulation of doxorubicin (Caelyx/Doxil), which is ap-
proved for use in the treatment of Kaposi’s sarcoma
and ovarian cancer, is in advanced clinical trials for
the treatment of metastatic breast cancer. This for-
mulation can reduce several of the side e¡ects that
accompany administration of standard DXR therapy
[5,6], while allowing the drug to accumulate in solid
tumours to a higher concentration than would the
free drug [7]. The liposomal encapsulation of DXR
has led to an increased response rate in Kaposi’s
sarcoma patients compared with those treated with
free DXR [8,9]. By coupling antibodies to the surface
of these Stealth liposomes, the latter can be made
into Stealth immunoliposomes for use as targetable
drug delivery systems [10].
The MUC-1 mucin, also known as the CA27.29
antigen, is one of the antigens that may be a good
candidate for use in targeting Stealth liposomal DXR
to breast tumour tissues. This antigen, which is ex-
pressed on the surface of normal epithelial cells, is
upregulated and aberrantly glycosylated in cancerous
cells. Tumour cells shed the MUC-1 antigen; blood
levels of the antigen are elevated in patients with
malignant breast cancer [11,12] and ovarian cancer
[13]. Serum levels of MUC-1 antigen are routinely
monitored as an indicator of relapse in breast cancer
patients. In this paper, a monoclonal antibody
(mAb) against MUC-1, B27.29, was tested for its
suitability for targeting immunoliposomes to breast
cancer cell lines transfected with the human MUC-1
antigen.
It has been demonstrated previously that long-cir-
culating liposomes of small size (approx. 100 nm in
diameter) will accumulate in solid tumours via a pas-
sive targeting mechanism by taking advantage of the
leaky vasculature of tumours undergoing angiogene-
sis [14^16]. While a passive targeting mechanism may
be e¡ective in increasing drug accumulation in tu-
mours once they begin to establish a vasculature,
liposomal drugs have no mechanism, other than a
sustained release mechanism, for accumulating in
metastatic cells prior to angiogenesis. We hypothe-
sized that the accumulation of liposomal drugs in
micrometastases, or in single metastatic cells migrat-
ing in blood or lymph, may be increased through the
use of liposomes targeted to cell surface antigens
such as MUC-1. Hence, pseudometastatic and meta-
static murine breast cancer tumour models were used
to investigate the therapeutic e⁄cacy of DXR-loaded
MUC-1-targeted sterically stabilized immunolipo-
somes (DXR-SIL[B27.29]) in the treatment of meta-
static disease.
2. Materials and methods
2.1. Monoclonal antibodies
B27.29 mAb, which binds to MUC-1 and has an
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IgG1 isotype [17], was provided by Biomira (Edmon-
ton, AB). MAb HMSA-5, an isotype-matched non-
speci¢c antibody that reacts with a melanosomal
component of normal and neoplastic melanocytes
[18] was a generous gift of Dr. K. Jimbo (Depart-
ment of Dermatology, University of Alberta, Ed-
monton, AB).
2.2. Mice
Six-to-eight-week-old female Balb/c cr Alt BM
mice were purchased from Health Sciences Labora-
tory Animal Services, University of Alberta. Female
C.B.-17/Icr severe combined immune de¢ciency
(SCID) mice were purchased from Taconic Farms
(Germantown, NY) and housed in a virus antigen-
free unit in the Health Sciences Laboratory Animal
Services facility, University of Alberta. All animal
protocols were approved by the Health Sciences An-
imal Policy and Welfare Committee, University of
Alberta, and were in accordance with the Guide to
the Care and Use of Experimental Animals published
by the Canadian Council on Animal Care.
2.3. Tumour cell lines
The GZHI cell line, obtained from Biomira, is
derived from the murine breast adenocarcinoma
cell line 410.4 by transfection with a full-sized con-
struct of the human MUC-1 gene [1,19]. GZHI cells
were cultured (in a humidi¢ed 37‡C incubator with a
5% CO2 atmosphere) in DMEM supplemented with
10% fetal bovine serum, penicillin (100 units/ml),
streptomycin (100 Wg/ml), and geneticin (400 Wg/ml)
(all supplied by Life Technologies, Burlington, ON).
The 4T1 cell line, a metastatic, thioguanine-resistant
subclone of the 410.4 cell line [2], was kindly pro-
vided by Dr. Fred Miller (Michigan Cancer Founda-
tion, Detroit, MI). This cell line has been shown to
metastasize via the blood [2] to several organs, in-
cluding the lungs. The 4T1-MUC1 cell line is a
MUC-1 transfectant, prepared with the same gene
construct as above. 4T1-MUC1 cells were cultured
in DMEM supplemented with 10% foetal bovine se-
rum, 60 WM thioguanine, 1 mM MEM non-essential
amino acids, penicillin (100 units/ml), streptomycin
(100 Wg/ml), and geneticin (400 Wg/ ml), all supplied
by Life Technologies. Geneticin is required as a se-
lective agent in the growth medium for both GZHI
and 4T1-MUC1 cell lines because the MUC-1 plas-
mid also carries geneticin resistance. However, the
GZHI cell line has been grown for up to 2 months
in medium without geneticin, and showed no loss of
MUC1 expression on the cell surface [19].
2.4. Flow cytometry (FACS) analysis.
The expression of the MUC-1 gene product on the
surface of GZHI and 4T1-MUC1 cells was analysed
by £ow cytometry (FACS). Brie£y, cells were cul-
tured several days until they reached log growth,
and then harvested by trypsinization. Aliquots of
cells (1U106/tube) were incubated for 30 min at
4‡C with 10 Wg of mAb B27.29. The cells were
washed with phosphate-bu¡ered saline (PBS), and
then incubated with goat anti-mouse FITC-labelled
secondary antibody (Sigma-Aldrich Canada, Oak-
ville, ON) for another 30 min at 4‡C. After washing,
cells were ¢xed with 0.5% formalin in PBS, and then
analysed on a FACScan (Becton Dickinson, San
Jose, CA) using Lysis II or CellQuest software.
2.5. Liposome preparation
Hydrogenated soy phosphatidylcholine (HSPC),
cholesterol (CHOL), methoxypolyethylene glycol (Mr
2000)-distearoylphosphatidylethanolamine (mPEG-
DSPE), and pyridyldithiopropionamide-polyethyl-
ene glycol (Mr 2000)-distearoylphosphatidyl etha-
nolamine (PDP-PEG-DSPE) were provided by
SEQUUS Pharmaceuticals (now Alza Corporation;
Menlo Park, CA). 125I-NaI and 3H-cholesteryl hexa-
decylether were purchased from Mandel Scienti¢c
(Guelph, ON). Antibody-targeted liposomes were
prepared by chemical coupling of the antibody to
the end of the PEG chain of PDP-PEG-DSPE, ac-
cording to a previously described method [20], with
modi¢cations as noted below. In some studies, lipo-
somes were loaded with the pH-sensitive dye HPTS
[21] rather than DXR, in order to determine the local
pH of the liposomal environment. Doxorubicin-
loaded liposomes, with or without a 3H-cholesteryl
hexadecylether tracer, were prepared by remote load-
ing using an ammonium sulphate gradient [22], then
activated with 20 mM DTT (dithiothreitol) for 30
min at room temperature. Excess DTT was removed
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by chromatography on a Sephadex G-50 column in
25 mM HEPES, 25 mM MES, and 140 mM NaCl
(pH 6.7). The mAb B27.29 was radiolabelled with
125I-NaI using Iodobeads (Pierce, supplied by Bio-
Lynx, Brockville, ON). MAb B27.29, with or with-
out a 125I-labelled mAb B27.29 tracer, was activated
using MCS (O-maleimidocaproic acid N-hydroxysuc-
cinimide ester, Sigma-Aldrich Canada) at a molar
ratio of 15:1 MCS:mAb for 30 min at room temper-
ature; the excess MCS was removed by gel ¢ltration
on a Sephadex G-50 (Amersham-Pharmacia Biotech,
Baie d’Urfe, PQ) column in 25 mM HEPES, 25 mM
MES, and 140 mM NaCl (pH 6.7). DXR-loaded
liposomes were coupled to mAb B27.29 (at a ratio
of 75^150 Wg mAb/Wmol phospholipid (PL) for use
during in vitro studies, or 40 Wg mAb/Wmol PL for
use during in vivo studies) for 1 h at room temper-
ature, followed by overnight storage at 4‡C. Un-
coupled mAb was separated from liposomes by chro-
matography on a Sepharose CL-4B (Amersham-
Pharmacia Biotech) column in HEPES bu¡er (25
mM HEPES, 140 mM NaCl, pH 7.4). Liposome
preparations were sized by dynamic light scattering
using a Brookhaven B190 Particle Sizer (Brookhaven
Instruments Corporation, Holtsville, NY); they had
an average diameter of 90^120 nm, and a polydisper-
sity index of less than 0.2.
Liposomal DXR, termed DXR-SL throughout this
paper, was the commercial preparation Doxil (in the
USA), sold as Caelyx in the rest of the world, and
was a generous gift from SEQUUS Pharmaceuticals
(now Alza Corporation).
2.6. Targeting studies
Liposomes for targeting studies were prepared
with high levels of the lipid tracer 3H-cholesteryl
hexadecylether (28 kBq/Wmol PL). Six-well tissue cul-
ture plates were seeded with 5U104 GZHI or 4T1-
MUC1 cells, then incubated for a further 2 days until
the wells were approx. 80% con£uent. Medium was
aspirated from the cells, after which non-targeted
control liposomes (SL) or targeted liposomes
(SIL[B27.29]) were added to cells at di¡erent concen-
trations of PL. Some incubations were done at 4‡C, a
temperature non-permissive for endocytosis. Alterna-
tively, incubations with SIL[B27.29] were done in
wells of cells preincubated with a 20 times excess of
free mAb B27.29, to block all speci¢c sites of attach-
ment of mAb. After 1 h incubation at 37‡C in a CO2
incubator, cells were washed 3 times with PBS and
harvested by trypsinization, as follows. Flasks of ad-
herent cells were washed with PBS containing 0.68
mM EDTA, then incubated in a small volume of
0.25% trypsin and 0.34 mM EDTA in PBS for ap-
prox. 5 min, until cells lifted o¡ the plate, at which
point the cells were resuspended in water. Cells were
transferred to scintillation vials, ACS (Aqueous
Counting Scintillant, Amersham Pharmacia Biotech)
was added, and 3H counts were used to calculate
speci¢c binding of immunoliposomes to cells.
2.7. Cytotoxicity assay
The IC50 concentrations of various formulations of
DXR were determined using the MTT cell prolifer-
ation assay [23]. Cells were seeded into 96-well plates
at 2U103 cells/well, and incubated for 1 day until the
cells were 50% con£uent. DXR-[SIL B27.29] was di-
luted with medium to di¡erent DXR concentrations,
added to wells, and incubated for 15 min at 37‡C in a
CO2 incubator. Controls were HEPES bu¡er (pH
7.4), non-targeted liposomal DXR (DXR-SL), or
free DXR. After the drug was washed from the cells,
wells were incubated for an additional 48 h before
cell viability was assessed [23].
2.8. Therapeutic studies using a pseudometastatic
model of breast cancer
Female Balb/c mice were purchased from the
Health Sciences Laboratory Animal Service, Univer-
sity of Alberta (Edmonton, AB). FACS analysis of
cells was conducted before cells were injected into
Balb/c mice, to con¢rm that the cells expressed
high levels of the target MUC-1 gene product. Path-
ology results showed that GZHI cells seeded and
grew in the mouse lung after intravenous (i.v.) injec-
tion, but growth was not observed in other organs
(not shown). These cells likely colonize the lung be-
cause this is the ¢rst capillary bed they encounter; we
do not have any direct evidence that these cells have
special a⁄nity to lung cells. GZHI cells were har-
vested in log phase growth by trypsin digestion
(0.25% trypsin, 0.34 mM EDTA, 137 mM NaCl,
5.7 mM KCl, and 7 mM NaHCO3), and injected
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via the tail vein into 6-week-old female mice, at
0.15U106 cells per mouse. Mice injected i.v. with
GZHI cells were monitored for shedding of MUC-
1 mucin in the circulation at 1 week intervals by an
EIA assay and no detectable mucin was found until
4 weeks after cells were injected (data not shown). In
single-treatment studies, injection of drug was 24 h
after injection of GZHI tumour cells; in multiple-
treatment studies, drug was injected on days 1,
8, and 15. Mice were divided into six groups of
¢ve mice each and groups received one of the fol-
lowing treatments: HEPES-bu¡ered saline; free
mAb B27.29; free DXR; DXR-SL; DXR-NSIL-
[HMSA-5], DXR-loaded liposomes targeted with a
non-speci¢c, isotype-matched antibody; or DXR-
SIL[B27.29]. Treatments were given i.v. at a dose
of 6 mg DXR/kg mice weight, except for the
HEPES-bu¡ered saline group and free mAb groups.
Treatment with mAb B27.29 was included as a con-
trol for the multiple-treatment study, using 8 Wg anti-
body/mouse, an amount equivalent to that coupled
to the injected dose of DXR-SIL[B27.29]. Survival
time was used as the main criterion for determining
treatment e⁄cacy.
For uridine uptake experiments, mice were injected
with GZHI cells via the i.v. route, then treated at 24 h
with various formulations of DXR (free drug, DXR-
SL, or DXR-SIL[B27.29]) at a dose of 6 mg/kg. At
25 days after treatment, mice were injected with 2 WCi
125I-dUrd (5-[125I]iododeoxyuridine, Mandel Scien-
ti¢c) in 0.2 ml of HEPES-bu¡ered saline; 4 h later
the lungs were removed and surface tumours
counted. Lungs were cut into small pieces, washed
with 10% trichloroacetic acid, and counted in a
Q-counter.
2.9. Therapeutic studies using a metastatic model for
breast cancer
When cells of the human MUC-1-transfected cell
line 4T1-MUC1 were implanted into the No. 4 mam-
mary fatpad (mfp) of female immune competent
Balb/c mice, no lung metastases were subsequently
detected. When the parent 4T1 cell line was similarly
implanted into the mfp of immune competent Balb/c
mice, metastases were observed in the lungs, as de-
scribed [2] (data not shown). Metastatic colonies
were detected in the lungs when the cells were im-
planted into the mfp of immunode¢cient (SCID)
mice, as described below. Therefore, all studies aimed
at treating metastases with targeted liposomes were
conducted in SCID mice.
Female SCID mice were anaesthetized with me-
thoxy£urane (Metofane, Janssen, Toronto, ON).
The right No. 4 mfp was exposed by making a small
(6^8 mm) incision just to the right of the midline. 105
4T1-MUC1 cells in 10 Wl of phosphate-bu¡ered sa-
line were injected directly into the mfp [24]. The in-
cision was closed with a wound clip and the mice
were monitored for tumour growth by palpation of
the mfp. The wound clip was removed 7 days after
the original implant. Tumour diameters were mea-
sured using callipers and tumour volume was deter-
mined using the equation: volume = 0.4 ab2, where
‘a’ is the larger diameter and ‘b’ is the smaller diam-
eter [25]. At 7^28 days after mfp implant, mice were
euthanized, at a point at which tumour diameters
were greater than 1 cm. Metastatic cells were de-
tected in blood, lungs, and peripheral lymph nodes
using a clonogenic assay [2]. In some experiments,
mfp tumours were generated by implantation of a
1 mm3 piece of 4T1-MUC1 tumour obtained from
a 14-day-old 4T1-MUC1 tumour growing in the mfp
of a female SCID mice.
Treatment of primary tumours using various for-
mulations of liposomal DXR was done by i.v. injec-
tion at 4, 10, and 17 days after implantation at a
DXR dose of 2.5 mg/kg. Treatment groups (¢ve
mice per group) included DXR-SL, DXR-
SIL[B27.29], HEPES-bu¡ered saline (pH 7.4), and
free DXR. Tumour volumes were measured regu-
larly. At 28 days after implantation, mice were sac-
ri¢ced and their lungs ¢xed in 10% formalin in PBS.
Lungs were evaluated for tumour colonies by prepar-
ing mid-sagittal sections of each of the largest lobes
and calculating the number of colonies per linear cm
of lung.
In some animals, the primary mfp tumour was
excised, under Metofane anaesthesia, at a time
when tumour metastasis was expected to have al-
ready occurred (see Section 3). Mice (groups of
four or ¢ve mice, as noted in the tables) subse-
quently received one or more i.v. injections of
DXR-SL, DXR-SIL[B27.29], HEPES-bu¡ered saline
(pH 7.4), or free DXR. They were then evaluated for
tumour regrowth and metastatic colonies in the lungs
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at a suitable time after removal of the primary tu-
mour.
3. Results
3.1. SIL[B27.29] binding and cytotoxicity
FACS analysis showed that the GZHI and 4T1-
MUC1 cell lines, both of which are transfected with
the MUC-1 gene, express a high level of the MUC-1
antigen, as shown by high binding of the mAb
B27.29 (Fig. 1). In vitro experiments showed that
SIL[B27.29] bound speci¢cally to GZHI and 4T1-
MUC1 cells with high binding levels, but non-tar-
geted liposomes (SL) had low binding (Fig. 2). Low-
er binding of the SIL[B27.29] was observed at 4‡C
than at 37‡C. However, attempts to show internal-
ization of SIL[B27.29] into an acid intracellular com-
partment (lysosomes, endosomes) using the pH-sen-
sitive dye HPTS [21] showed only a modest decrease
in pH (from pH 7.4 to pH 6.9 in 4 h).
Our in vitro cytotoxicity study of DXR-
SIL[B27.29] to GZHI cells is meant to more closely
mimic the in vivo situation where rapid redistribu-
tion of free DXR occurs. We exposed cells to various
DXR formulations, at the IC50 concentration of the
free drug (1.6 Wg/ml), for 15 min at 37‡C, su⁄cient
time for immunoliposomes to bind to the cells.
DXR-SIL[B27.29] inhibited the growth of GZHI
cells by 57%, compared with 14% and 8% inhibition
for SL-DXR and NSIL-DXR[HMSA-5] respectively
(P6 0.01). Thus the toxicity of SIL-DXR[B27.29]
Fig. 2. Binding of antibody-targeted liposomes SIL[B27.29] to
(A) GZHI cells, and (B) 4T1-MUC1 cells in vitro at various
temperatures. 8, SL 4‡C; R, SIL 4‡C; F, SL 37‡C; S, SIL
37‡C; b, 2-fold excess free mAb+SIL.
Fig. 1. Binding of mAb B27.29 to (A) GZHI and (B) 4T1-
MUC1 cells, as determined by FACS. Control, solid line; sec-
ondary antibody only, dotted line; mAb B27.29, dashed line.
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was comparable with that of free DXR. These results
suggest that not only were a large number of DXR-
SIL[B27.29] bound to cells, but su⁄cient DXR was
released from liposomes, either surface bound or in-
ternalized, to be very cytotoxic.
3.2. In vivo therapeutic studies in a pseudometastatic
model for breast cancer (GZHI)
Therapeutic experiments were performed as single
(Fig. 3A) or multiple administrations (Fig. 3B) of
DXR at 6 mg/kg, the latter given on days 1, 8, and
15. The mean survival time (MST) was 29.6 days for
control mice injected with HEPES-bu¡ered saline
(pH 7.4) (Fig. 3A,B). Free DXR treatment increased
the MST (36.8 or 40.6 days for single or multiple
injections, P6 0.05 or 0.01 respectively, compared
with control). Treatment of mice with DXR-SL re-
sulted in signi¢cantly longer MST compared with
free DXR treatment (46.2 or 48.7 days for single or
multiple injections respectively, P6 0.05 compared
with free DXR). In mice treated with targeted lipo-
somes, single or multiple injections of DXR-
SIL[B27.29] resulted in signi¢cant increases in MST
(62.4 or 64.6 days respectively, P6 0.01 compared
with DXR-SL), but there was no statistically signi¢-
cant di¡erence between single- and multiple-injection
regimens. It may be that the ¢rst treatment is the
critical one, when the tumours are quite small, and
the SILs do not have to penetrate deep within a large
tumour to reach all cells [26^28]. Further treatments
with DXR-SIL[B27.29] may be ine¡ective as these
liposomes may not e¡ectively penetrate the multiple
cell layers of the larger tumour, being mostly bound
at the periphery of the tumour.
Although the MUC1 antigen is a weak immuno-
gen to T cells and B cells [29,30], injection of lipo-
some-mAb B27.29 conjugates in immune-competent
mice may result in the complexing of circulating
MUC1, which is shed by the developing tumour,
with the antibody, thus initiating B- and T-cell-medi-
ated immune responses directed against the tumour.
To test whether the targeting antibody initiated an
immune attack on the developing GZHI tumours,
one group was treated with an amount of free
mAb B27.29 equivalent to that which was attached
to DXR-SIL[B27.29], in multiple injections. No dif-
ference between the life span of the HEPES-bu¡ered
saline-treated group of mice and that of mice treated
with free mAb B27.29 was observed. Thus we con-
cluded that the amount of mAb introduced on the
SILs was insu⁄cient to elicit a strong immune re-
sponse from the mice.
Mice treated with DXR-NSIL[HMSA-5] had a
survival time similar to that of the DXR-SL group,
indicating that removal of SILs from circulation is
not signi¢cantly more rapid than that of SLs. How-
ever, we tried to keep the amount of mAb coupled to
the surface of SILs about 40 Wg/Wmol phospholipid
Fig. 3. Survival of Balb/c mice injected i.v. with 0.15U106
GZHI cells, and treated with either (A) a single i.v. injection
of various formulations of DXR, 24 h after injection of cells,
or (B) three i.v. injections of various formulations of DXR, at
24 h, 8 days and 15 days after i.v. injection of cells (¢ve mice
per group). Treatments are: a, HEPES-bu¡ered saline; b, free
DXR; R, DXR-SL; F, DXR-NSIL[HMSA-5]; 8, DXR-SIL-
[B27.29]+DXR-SL; S, DXR-SIL[B27.29].
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(approx. 25 mAb/liposome) in order to prevent Fc-
mediated clearance of immunoliposomes from the
circulation [20].
We also treated one group of mice with a combi-
nation of 3 mg DXR/kg as DXR-SL plus 3 mg
DXR/kg as DXR-SIL[B27.29]. The results showed
a MST that was intermediate between that obtained
with DXR-SIL[B27.29] versus DXR-SL (Fig. 3A,B).
Because of possible di¡erences in penetration of SILs
vs. SLs into solid tumours, we anticipated that for a
well-established tumour the DXR-SL could di¡use
further through the tumour interstitial space than
targeted liposomes, which would experience a ‘bind-
ing site barrier’ [27]. However, in this study, combi-
nation treatment showed no improvement over the
targeted DXR-SIL[B27.29] alone.
To determine the e¡ect of the various drug treat-
ments on growth of GZHI tumours in the lung,
125I-dUrd uptake experiments were performed in
tumour-bearing mice (Fig. 4A). Uptake into lung
of 125I-dUrd has been established to be directly pro-
portional to the number of seeded tumour cells [31].
HEPES-bu¡ered saline-treated tumour-bearing con-
trol mice had signi¢cantly higher uridine uptake than
tumour-free mice (P6 0.01). Mice treated with
DXR-SIL[B27.29] had a signi¢cant decrease in uri-
dine uptake compared with either untreated tumour-
bearing mice (P6 0.01) or mice treated with either
free DXR (P6 0.05) or DXR-NSIL[HMSA-5]
(P6 0.01). The number of tumour nodules per lung
in the various treatment groups was also compared.
DXR-SIL[B27.29] was able to reduce the number of
tumour nodules compared with DXR (P6 0.001) or
DXR-SL (P6 0.01) treatment (Fig. 4B).
3.3. In vivo therapeutic studies in a metastatic model
for breast cancer (4T1-MUC1)
The number of metastatic cells located in the lung
at various time points after implantation of 105 cells
into the mfp of SCID mice was determined by a
clonogenic assay. Although the number of clones
isolated from lungs was highly variable, metastatic
cells were located in the lungs of all mice by 14
days after injection of tumour cells into the mfp.
Fig. 5. Volume of 4T1-MUC1 mfp tumours in SCID mice
treated with various formulations of doxorubicin at a DXR
dose of 2.5 mg/kg, on days 4, 10 and 17 after implant of 105
tumour cells into the mfp. Volumes were calculated using the
formula volume = 0.4 ab2, where ‘a’ is the larger diameter and
‘b’ is the smaller diameter.
Fig. 4. Evaluation of lung tumours in mice 25 days after injec-
tion with 0.15U106 GZHI cells i.v., and treated at 24 h with a
single injection of various formulations of DXR at 6 mg/kg.
(A) 125I-dUrd counts in lungs. 125I-dUrd was injected via the
tail vein; 4 h later mice were sacri¢ced. Lungs were weighed
and surface tumours counted. The lungs were then minced,
washed with 10% TCA, and counted in a Q-counter. (B) Num-
ber of tumour nodules per lung.
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By 25 days after injection of cells into the mfp, tu-
mours were visible on the surface of lungs.
Various treatments (free DXR, DXR-SL, DXR-
SIL[B27.29] or HEPES-bu¡ered saline, at a DXR
dose of 2.5 mg/kg) were injected i.v. on days 4, 10
and 17 after implantation of 4T1-MUC1 cells into
the mfp of SCID mice. Tumour volumes for the
various treatment groups were determined (Fig. 5).
DXR-SL and DXR-SIL[B27.29] were equally e¡ec-
tive in preventing growth of the primary tumour,
while free DXR was ine¡ective. Histological exami-
nation of the lungs at 28 days after implantation
showed that both DXR-SIL[B27.29] and DXR-SL
were able to completely prevent the seeding of meta-
stases into the lungs. By comparison, treatment with
free DXR or HEPES-bu¡ered saline resulted in
3.2 þ 1.8 and 8.2 þ 10.2 colonies/linear cm respec-
tively.
3.4. Treatment of metastases after surgical removal of
primary tumour
Complete surgical removal of the large primary
tumour at 14 days without tumour regrowth was
not possible when suspensions of cells were injected
into the mfp. The 4T1-MUC1 cell line grows very
aggressively in the mouse mfp (see Fig. 5, HEPES-
bu¡ered saline treatment group). Surgical removal of
the primary tumour at 8 days after implantation (the
earliest time point at which lung metastases could be
detected), followed by treatment on days 1, 8, and 15
with di¡erent formulations of DXR (2.5 mg/kg), was
then attempted in order to see if the growth of lung
metastases could be prevented. The mice were also
monitored for regrowth of the primary tumour. At
22 days after the surgery (30 days post implantation),
the presence of metastases in lung was evaluated by
histopathology. Regrowth of the primary tumour oc-
curred in all mice in the groups treated with HEPES-
bu¡ered saline, DXR-SIL[B27.29] or free DXR.
Only in the group treated with DXR-SL were there
any animals in which the primary tumour did not
regrow (50% tumour-free, n = 4). Although it was
our intention to treat only the metastatic disease fol-
lowing removal of the primary tumour (adjuvant
model of chemotherapy), the regrowth of the pri-
mary tumour prevented this. It was not possible to
remove a wide margin of normal tissue from around
a mouse mfp tumour, partly because mice are quite
small and partly because the tumours that develop in
this model are relatively large at 8^14 days.
As an alternative approach, we implanted a 1 mm3
explant of 4T1-MUC1 tumour into the mfp of SCID
mice. It was hoped that the primary tumour, which
developed from such an implant, would have cleaner
margins and be easier to remove than the tumour
that developed from the implantation of a cell sus-
pension. 4T1-MUC1 colonies in lungs were ¢rst de-
tected on day 8; three of three mice had tumour cells
in their lungs by day 11. This observation is similar
to the time for detection of metastases after implant
of a cell suspension in the mfp, but the standard
deviations of colony numbers were smaller, implying
more reproducible metastases.
The therapeutic e⁄cacy of DXR-SIL[B27.29] in
treatment of metastases following surgical removal
of the primary tumour 8 days after implantation of
1 mm3 explants was examined (Tables 1 and 2). Re-
growth of the primary tumour was observed in all
mice treated with either DXR-SIL[B27.29], free
Table 1
Regrowth of primary tumour after surgical removal of tumours grown from 1 mm3 explants
Type of treatment (number of mice) Number of mice with no regrowth Number of mice with regrowth % regrowth
DXR-SIL[B27.29] (n = 5) 0 5 100
DXR-SL (n = 5) 2 3 60
Free DXR (n = 5) 0 5 100
HEPES-bu¡ered saline (n = 4) 0 4 100
Explants of 4T1-MUC1 tumours (1 mm3) were implanted into the mfp of 20 female SCID mice. Eight days after implantation, pri-
mary tumours were removed. The mice were injected i.v. with various formulations of DXR at 2.5 mg DXR/kg 24 h after surgery,
then at weekly intervals for a total of three treatments per group. The mice were monitored for regrowth of the primary tumour; at
20 days after surgery (28 days post implantation), lung metastases were evaluated by histopathology.
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DXR, or HEPES-bu¡ered saline (Table 1). Only
mice treated with DXR-SL showed a reduction in
tumour regrowth (40% tumour regrowth, n = 5). At
20 days after surgical removal of the primary tumour
and subsequent treatment (28 days after implant of
tumour explants into the mfp) histopathological
staining was used to identify tumour colonies in the
lungs. All animals, in all groups (including those
mice in which the primary tumour did not regrow,
i.e., the DXR-SL group), were found to have tumour
colonies in their lungs (Table 2). The numbers of
colonies varied from 0.25 to 1.1 per linear cm of
lung, with no signi¢cant di¡erences between the var-
ious treatment groups.
4. Discussion
Several researchers have used targeted long-circu-
lating liposomes to deliver anti-tumour drugs in ex-
perimental animal models of disease [32^39]. Target-
ing moieties may be attached at the surface of the
liposome or at the terminus of the hydrophilic PEG-
lipid anchor conjugate; various coupling mechanisms
can be used, resulting in random or speci¢c orienta-
tion of the targeting molecule [40,41]. All these meth-
ods a¡ect e⁄ciency of coupling, targeting in vivo and
clearance of liposomes from the circulation. The cou-
pling method chosen for use in this paper is one
which gives good coupling e⁄ciency, long-circulating
pharmacokinetics in vivo, and retention of binding
after coupling [42].
Treatment of solid tumours with targeted lipo-
somal drug presents unique problems. The penetra-
tion of liposomes into a tumour may be limited by
high internal hydrostatic pressure [15,43]. However,
there is ample evidence that non-targeted Stealth
liposomes do penetrate solid tumours [44] [15], so
this phenomenon does not completely prevent deliv-
ery of drug. Targeted liposomes may bind to cell
surface receptors at the tumour periphery, preventing
them from reaching cells in the interior of the tu-
mour [27]. In the models used in this study, we
wanted to evaluate the usefulness of immunolipo-
somes in the treatment of solid tumours at a stage
at which the tumours are pre-angiogenic, such as
would be found at the early stage of metastasis.
The pseudometastatic model is designed to test the
feasibility of this approach, i.e., the treatment of lung
micrometastases soon (1 day) after they seed in the
lung following i.v. injection.
The nature of the cellular epitope to which the
liposomes are targeted will greatly in£uence the de-
livery of the liposomal drug. Drug may directly dif-
fuse out of the targeted liposomes bound to the tar-
get cell surface and be taken up by the target cells, in
a process dependent upon the drug release rate of the
liposome formulation, as well as factors such as cell
permeability to the drug. Alternatively, the drug-
liposome package may be taken up by the cell after
binding to an internalizing receptor [35,37,45]. In the
case of an internalized receptor-immunoliposome
complex, targeted liposomes will be processed by
the cell’s lysosomal or endosomal systems so the
drugs that escape degradation may be released inside
the cell. Internalizing epitopes are thought to be
more e⁄cient at increasing intracellular drug concen-
trations because entry of the drug into the cells is not
dependent upon leakage and passive di¡usion. It has
been observed by Litvinov and Hilkens [46] that the
Table 2
Number of metastatic colonies in lungs at day 20 (28 days after implantation of primary tumour)
Type of treatment
(number of mice)
Number of metastatic colonies
per linear cm of lung, in left lobe
Number of metastatic colonies
per linear cm of lung, in largest right lobe
DXR-SIL[B27. 29] (n = 5) 0.251 þ 0.293 0.504 þ 0.597
DXR-SL (n = 5) 0.530 þ 0.292 0.950 þ 0.376
Free DXR (n = 4) 0.413 þ 0.223 1.073 þ 0.93
HEPES-bu¡ered saline (control) (n = 3) 0.438 þ 0.49 0.220 þ 0.296
The primary tumour was surgically removed on day 8 after implantation of a 1 mm3 explant of 4T1-MUC1 tumour into the mfp of
SCID mice. Mice were treated i.v. 24 h after surgery, then at weekly intervals for a total of three treatments per group, at a DXR
dose of 2.5 mg/kg.
BBAMEM 77996 26-1-01
E.H. Moase et al. / Biochimica et Biophysica Acta 1510 (2001) 43^5552
incompletely glycosylated intermediate of the MUC-
1 epitope is internalized and then recycled to the sur-
face of the ZR-75-1 human mammary carcinoma cell
line as additional sialyl groups are attached to the
mucin. These authors show that 0.9% of the surface
episialin (also known as MUC-1) is recycled per min-
ute, probably via a cellular compartment containing
sialyltransferase, presumably the trans-Golgi and
trans-Golgi network [47]. In the study reported
here, MUC-1 expression on the GZHI and 4T1-
MUC1 cell lines has been induced by transfection
of mouse cells with the human MUC-1 gene. It is
not clear whether the mechanism of MUC-1 sialyla-
tion in mouse cells will proceed in a similar fashion
to that observed in human cells. If receptor recycling
does occur in our model system, it is unlikely that the
rate of MUC-1 recycling is rapid enough to result in
e¡ective internalization of DXR-SIL[B27.29] bound
to the cell surface. When GZHI cells were incubated
with B27.29-targeted immunoliposomes loaded with
the pH-sensitive dye HPTS rather than DXR, we
observed only a slight drop in the internal pH of
the liposomes. The higher amount of binding to
GZHI and 4T1-MUC1 cells observed for
SIL[B27.29] at 37‡C versus 4‡C suggests that some
internalization of the liposomes may occur, since 4‡C
is a non-permissive temperature for receptor-medi-
ated internalization; the additional binding at 37‡C
may be due to di¡erences in the binding kinetics at
the two temperatures, and likely does not re£ect a
signi¢cant amount of internalization.
In the metastatic process, the primary tumour
sheds cells that have the capacity to reattach and
develop into secondary tumours in locations distant
from the primary tumour. Our goal was to test the
hypothesis that targeted liposomal DXR could be
useful, as an adjuvant to the surgical removal of
the primary tumour, in the treatment of secondary
tumours that had already seeded at the time of sur-
gical removal, but were still very small and poorly
vascularized.
The ¢nding that non-targeted liposomal doxorubi-
cin was as e¡ective as targeted liposomal DXR in
preventing growth of primary mfp tumours (Fig. 5)
is supported by results in another solid tumour mod-
el studied by our group, the human ovarian cancer
cell line Caov.3, grown in nude mice as a subcuta-
neous implant [10]. In our experiments in the ovarian
cancer model, targeted liposomal DXR was slightly
less e¡ective in preventing growth of the subcutane-
ous tumour than non-targeted liposomal DXR.
In our metastatic model, metastasis occurs via the
blood, with the main site of seeding of secondary
tumours being the lungs [2]. The number of lung
colonies increased with time after implant of the pri-
mary tumour. These lung tumours were expected to
be amenable to treatment with targeted liposomal
DXR, as were the small tumours in the pseudometa-
static model. In the true metastatic model, the seed-
ing of secondary tumours is a more continuous pro-
cess than an i.v. bolus of cells, although the actual
tumour burden is considerably smaller (0.15U106
cells seeded i.v. in the pseudometastatic model vs. a
¢nding of in the order of 100 colony-forming units in
the lungs at 7 days in the metastatic model. We hy-
pothesize that successful treatment of micrometasta-
ses in the lungs of mice following mfp implantation
would depend on treating the mice at a time when
the secondary tumours are small, poorly vascular-
ized, and still in contact with the lung’s blood circu-
lation.
A major limitation of the metastatic model de-
scribed in this paper is our inability to completely
remove the primary tumour. This made it impossible
to treat only the secondary metastases with targeted
liposomal drug, because the regrowing primary tu-
mour continually shed more tumour cells into the
circulation. The dosing regimen of once a week
may not be su⁄cient to intercept single circulating
tumour cells and small, non-vascularized tumours,
both of which appeared to be amenable to treatment
by targeted liposomes in the pseudometastatic model.
Targeted Stealth liposomes are themselves a contin-
uous delivery system, with a plasma half-life of in the
order of 7^9 h [20]; therefore, a more practical deliv-
ery regimen would possibly be twice weekly, given
what we know about the pharmacokinetics of these
liposomes. In the pseudometastatic model, we would
not expect multicellular tumours to have developed
in the mouse lung at 24 h after i.v. injection of a cell
suspension.
Di¡erences in response to targeted liposomal treat-
ment, between immune-competent mice treated with
GZHI cells and immunocompromised SCID mice,
may re£ect di¡erences in the immune status of the
mice. In the immune-competent mice, the immune
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system may play a role in rejection of GZHI tumours
when targeted liposomes bind to these cells, as the
GZHI cells express a foreign (human) MUCI gene.
There are considerable di¡erences in DXR toler-
ance between conventional and SCID mice [25]. Con-
ventional mice can readily tolerate a doxorubicin
dose of 6 mg/kg, whereas SCID mice, which are de-
¢cient in DNA repair, cannot tolerate more than
2.5^3 mg/kg without dose-limiting toxicities [25]. In
SCID mice bearing the metastatic model, the dose
of liposomal DXR may be below the dose required
for a successful therapeutic outcome. This could
also help to explain the di¡erential success in treat-
ing the pseudometastatic model vs. the metastatic
model.
One intriguing observation was that both targeted
and non-targeted liposomal DXR were able to pre-
vent the seeding of metastases into lungs when the
primary tumour was left in place. Treatment with
free DXR was not able to achieve this result. This
suggests that liposomal DXR may be useful in adju-
vant chemotherapy when complete surgical removal
of the primary tumour is possible. These results
should be pursued further.
The use of immunoliposomes in another mouse
model for breast cancer has been described [48]. In
their study, Park et al. found that anti-HER2 immu-
noliposomes accumulated in Her2 (c-erB-2, neu)-
overexpressing tumours growing in nude mice,
when injected i.v., and that DXR-loaded anti-
HER2 immunoliposomes were signi¢cantly more cy-
totoxic to the tumours than were untargeted DXR-
loaded liposomes. This probably re£ects their ¢nding
that anti-HER2 immunoliposomes are avidly inter-
nalized by HER2-overexpressing cells, delivering
drug into the cell. In our system, if internalization
does take place, it is probably at a signi¢cantly slow-
er rate than internalization in the HER2 system.
In conclusion, liposomal DXR targeted against the
MUC-1 epitope appeared to be e¡ective in treating
early lung metastases in a pseudometastatic model of
breast cancer and in preventing the growth of lung
metastases in a metastatic breast cancer model when
no attempt was made to surgically remove the pri-
mary tumour. However, limitations to the access of
the targeted liposomes to tumour cells in the primary
tumour compromised their therapeutic e⁄cacy in
treating the more advanced lesions and did not give
them a selective advantage over non-targeted lipo-
somes.
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